A new blood test, called PromarkerEso, could be a game-changer in the fight against esophageal adenocarcinoma (EAC), according to a study published in the journal Proteomes. The test offers a non-invasive way to diagnose the disease early, potentially helping to save lives and reduce the burden on healthcare systems.
The Challenge of a Silent Killer
EAC is a particularly aggressive cancer, and its incidence has skyrocketed by 600% in Western countries since the 1970s. The biggest problem? The disease is a “silent killer,” often showing no symptoms in its early stages. This often leads to a delayed diagnosis and poor prognosis, with a five-year survival rate of less than 20%
Currently, the gold standard for diagnosis is an endoscopy with a biopsy, a procedure that is both invasive and expensive. But with this new blood test, that could change.
How PromarkerEso Works
Instead of a hospital procedure, PromarkerEso requires only a simple blood sample. It works by measuring the levels of four key glycoprotein biomarkers: alpha-1-antitrypsin, alpha-1-antichymotrypsin, complement C9, and plasma kallikrein. These proteins are known to have links to EAC. The test then combines this information with a patient’s age, sex, and BMI to create an overall risk score.
The results are categorized into three risk levels: low, moderate, and high. This clear classification aims to give patients and doctors a better roadmap for what to do next10.
Promising Results from Clinical Trials
The PromarkerEso test was clinically validated on 259 samples from three independent cohorts and showed excellent results. The test was highly sensitive, meaning it was great at correctly identifying people who have EAC. In the validation cohorts, its sensitivity was as high as 99.9%.
It also proved to be very specific, accurately identifying those without the disease. In one validation cohort, its specificity reached 99%. The test’s accuracy was also very high, with a strong area under the curve (AUC) of 0.98 in one of the validation cohorts.
A Potential Path to Better Care
The researchers believe PromarkerEso could be a valuable tool for healthcare providers. For example, a patient with a low-risk score might be able to avoid an unnecessary endoscopy. Conversely, a high-risk score could help doctors prioritize a patient for a timely endoscopy and biopsy, potentially reducing wait times and improving outcomes.
This new approach represents a significant step forward in the diagnosis of EAC, offering a more convenient and less invasive alternative for patients1. While further studies are needed, particularly in diverse demographic groups, the initial findings suggest PromarkerEso could soon become a critical part of the standard diagnostic process.
